Suspended

IUGRIntra Uterine Growth Restriction. Minimum Required Evidence-based Care and Neonatal Prognosis: Impact of Healthcare Pathways

What is being collected

Data Collection

Collected from past medical records and data - Retrospective

Who is being recruted

Urogenital Diseases+6

+ Female Urogenital Diseases and Pregnancy Complications

+ Fetal Diseases

+6 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.

Observational

Study Start: September 2018

See protocol details

Summary

Principal SponsorHospices Civils de Lyon

Study ContactMuriel DORET, Prof.

Last updated: January 27, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: September 1, 2018

Actual date on which the first participant was enrolled.

Intrauterine growth restriction (IUGR) is associated with an increase in perinatal mortality and morbidity, as well as longer-term neurological, cognitive, cardiovascular and endocrine complications. In Europe, about 400,000 pregnancies per year are complicated by IUGR. However, antenatal diagnosis seems insufficient in clinical practice, making it impossible to recognize up to 75% of foetuses with IUGR. At a time when the use of good clinical practice has demonstrated a significant improvement in neonatal survival without severe morbidity, foetuses with IUGR are less likely to receive optimal care. Our hypothesis is that the rate of IUGR diagnosed underestimates the rate of actual IUGR.

Official TitleIntra Uterine Growth Restriction. Minimum Required Evidence-based Care and Neonatal Prognosis: Impact of Healthcare Pathways

NCT03866863

Principal SponsorHospices Civils de Lyon

Study ContactMuriel DORET, Prof.

Last updated: January 27, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

31052 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsFetal DiseasesFetal Growth RetardationGrowth DisordersCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPathologic ProcessesPregnancy ComplicationsPathological Conditions, Signs and Symptoms

Criteria

2 inclusion criteria required to participate

All birth more than 24 + 0 weeks of amenorrhea at the maternity ward of the hospital Femme-Mère-Enfant

from 1st of january 2011 to 31 december 2017.

4 exclusion criteria prevent from participating

Infants born out of the hospital and secondarily hospitalized in the hospital Femme-Mère-Enfant .

Multiple pregnancies,

children with congenital fetal anomalies

pregnancies without first trimester ultrasound (to date the pregnancy)

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Hôpital Femme Mère Enfant

Bron, FranceOpen Hôpital Femme Mère Enfant in Google Maps

SuspendedOne Study Center